|7.11|| +0.27 / +3.95%|
NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
|Charles J. Link||Chairman, Chief Executive & Scientific Officer|
|Nicholas N. Vahanian||President & Director|
|John B. Henneman||Chief Financial Officer, Secretary & Executive VP|
|Eugene P. Kennedy||Chief Medical Officer|
|Thomas P. Monath||Chief Scientific Officer|